Masimo seeks to boost automation of newborn screenings in Europe

Masimo (NSDQ:MASI) announced earlier this week that it launched a new patient monitoring and connectivity hub.

The first application of Dual SET Oximetry for Root offers a significant advancement to the Masimo SET-guided critical congenital heart disease (CCHD) screening, the company said in a news release.

Masimo will combine the platform with the CE-marked Masimo SET MOC-9 module and the Eve CCHD newborn screening application for Root to enhance the automation of newborn screenings using Dual SET Oximetry.

Masimo designed its Eve CCHD newborn screening application to simplify the CCHD screening process with step-by-step visual instructions, animations and a detailed display of screening results. The company said this offers standardized and enhanced clinical workflows, improved consistency and the potential to reduce calculation errors.

Additionally, Masimo touts Eve’s ability to incorporate perfusion index into screening, potentially increasing sensitivity to the detection of CCHD. The platform displays on Root’s large, high-resolution screen with a built-in barcode scanner to automatically associate patients with screening results and automate the transfer of those results to electronic medical records (EMRs).

“As a neonatologist who has worked nationally and internationally in the early diagnosis and treatment of hypoxemic and hyperoxemic conditions that affect neonates in order to improve neonatal survival and quality of life for these fragile infants, I know that Masimo SET measure-through motion technology’s accuracy and reliability have not only enabled CCHD screening with pulse oximetry, but have helped dramatically reduce retinopathy of prematurity (ROP),” Masimo VP of Medical Affairs Dr. Augusto Sola said in the release.

“SET provides reliable, high-quality monitoring to prevent serious long-term morbidities and is now the standard of care for CCHD newborn screenings and ROP,” Sola said. “… The Eve application on Root is automated and therefore simplifies and systematizes the screening process. Millions of newborn babies and their families throughout the world will be greatly benefited by this unique solution.”